
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2006071/publications.pdf Version: 2024-02-01



ANCELO EASSIO

#	Article	IF	CITATIONS
1	The obesity paradox and osteoporosis. Eating and Weight Disorders, 2018, 23, 293-302.	1.2	142
2	Vitamin D Status and SARS-CoV-2 Infection and COVID-19 Clinical Outcomes. Frontiers in Public Health, 2021, 9, 736665.	1.3	108
3	Osteoporosis in Rheumatic Diseases. International Journal of Molecular Sciences, 2019, 20, 5867.	1.8	76
4	Periostin: The bone and beyond. European Journal of Internal Medicine, 2017, 38, 12-16.	1.0	55
5	Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes. Diabetes and Metabolism, 2019, 45, 347-355.	1.4	47
6	Association between environmental air pollution and rheumatoid arthritis flares. Rheumatology, 2021, 60, 4591-4597.	0.9	43
7	In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls. Clinical Rheumatology, 2017, 36, 2377-2381.	1.0	38
8	Inhibition of tumor necrosis factor-alpha (TNF-alpha) in patients with early rheumatoid arthritis results in acute changes of bone modulators. International Immunopharmacology, 2019, 67, 487-489.	1.7	37
9	Association Between Short-term Exposure to Environmental Air Pollution and Psoriasis Flare. JAMA Dermatology, 2022, 158, 375.	2.0	35
10	Effects of biological and targeted synthetic DMARDs on bone loss in rheumatoid arthritis. Pharmacological Research, 2019, 147, 104354.	3.1	30
11	Osteoporosis in 10 years time: a glimpse into the future of osteoporosis. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210835.	1.2	30
12	18F-fluoride PET/CT for detection of axial involvement in ankylosing spondylitis: correlation with disease activity. Annals of Nuclear Medicine, 2016, 30, 430-434.	1.2	29
13	Pharmacokinetics of Oral Cholecalciferol in Healthy Subjects with Vitamin D Deficiency: A Randomized Open-Label Study. Nutrients, 2020, 12, 1553.	1.7	29
14	Association between long-term exposure to air pollution and immune-mediated diseases: a population-based cohort study. RMD Open, 2022, 8, e002055.	1.8	29
15	New Strategies for the Prevention and Treatment of Systemic and Local Bone Loss; from Pathophysiology to Clinical Application. Current Pharmaceutical Design, 2018, 23, 6241-6250.	0.9	27
16	Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women. Bone, 2019, 123, 191-195.	1.4	26
17	Risk of fragility fractures in obesity and diabetes: a retrospective analysis on a nation-wide cohort. Osteoporosis International, 2020, 31, 2113-2122.	1.3	26
18	Association between exposure to fine particulate matter and osteoporosis: a population-based cohort study. Osteoporosis International, 2022, 33, 169-176.	1.3	26

#	Article	IF	CITATIONS
19	The ultrasonographic study of the nail reveals differences in patients affected by inflammatory and degenerative conditions. Clinical Rheumatology, 2019, 38, 913-920.	1.0	25
20	The negative bone effects of the disease and of chronic corticosteroid treatment in premenopausal women affected by rheumatoid arthritis. Reumatismo, 2016, 68, 65-71.	0.4	24
21	Drug-induced osteonecrosis of the jaw: the state of the art. Reumatismo, 2017, 69, 9.	0.4	24
22	Teriparatide and denosumab combination therapy and skeletal metabolism. Osteoporosis International, 2016, 27, 3301-3307.	1.3	23
23	Ultrasonography of the nail unit reveals quantitative and qualitative alterations in patients with psoriasis and psoriatic arthritis. Medical Ultrasonography, 2018, 20, 177.	0.4	23
24	Vitamin D: not just bone, but also immunity. Minerva Medica, 2016, 107, 452-460.	0.3	22
25	<scp>V</scp> itamin D levels strongly influence bone mineral density and bone turnover markers during weight gain in female patients with anorexia nervosa. International Journal of Eating Disorders, 2017, 50, 1041-1049.	2.1	21
26	Secukinumab produces a quick increase in WNT signalling antagonists in patients with psoriatic arthritis. Clinical and Experimental Rheumatology, 2019, 37, 133-136.	0.4	20
27	Bone Geometry, Quality, and Bone Markers in Children with Type 1 Diabetes Mellitus. Calcified Tissue International, 2018, 102, 657-665.	1.5	18
28	Nail ultrasonography for psoriatic arthritis and psoriasis patients: a systematic literature review. Clinical Rheumatology, 2020, 39, 1391-1404.	1.0	18
29	Osteoporosis in Inflammatory Arthritides: New Perspective on Pathogenesis and Treatment. Frontiers in Medicine, 2020, 7, 613720.	1.2	18
30	ls central sensitization an important determinant of functional disability in patients with chronic inflammatory arthritides?. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2199325.	1.2	18
31	The Emerging Roles of Endocrine Hormones in Different Arthritic Disorders. Frontiers in Endocrinology, 2021, 12, 620920.	1.5	18
32	Parathyroid hormone is a determinant of serum Dickkopf-1 levels in ankylosing spondylitis. Clinical Rheumatology, 2018, 37, 3093-3098.	1.0	16
33	Acute Effects of Glucocorticoid Treatment, TNFα or IL-6R Blockade on Bone Turnover Markers and Wnt Inhibitors in Early Rheumatoid Arthritis: A Pilot Study. Calcified Tissue International, 2020, 106, 371-377.	1.5	15
34	Osteoporosis: an Independent Determinant of Bone Erosions in Rheumatoid Arthritis?. Journal of Bone and Mineral Research, 2017, 32, 2142-2143.	3.1	14
35	Long-term Effects of Neridronate in Adults with Osteogenesis Imperfecta: An Observational Three-Year Italian Study. Calcified Tissue International, 2017, 100, 341-347.	1.5	13
36	Treatment with neridronate in children and adolescents with osteogenesis imperfecta: Data from open-label, not controlled, three-year Italian study. Bone, 2017, 103, 144-149.	1.4	13

#	Article	IF	CITATIONS
37	Environmental Air Pollution Is a Predictor of Poor Response to Biological Drugs in Chronic Inflammatory Arthritides. ACR Open Rheumatology, 2021, 3, 451-456.	0.9	13
38	Diffuse Idiopathic Skeletal Hyperostosis (DISH) in Type 2 Diabetes: A New Imaging Possibility and a New Biomarker. Calcified Tissue International, 2021, 108, 231-239.	1.5	12
39	Vitamin D and disease severity in coronavirus disease 19 (COVID-19). Reumatismo, 2021, 72, 189-196.	0.4	12
40	Pharmacological management of osteoporosis in postmenopausal women: The current state of the art. Journal of Population Therapeutics and Clinical Pharmacology, 2019, 26, e1-e17.	1.4	12
41	Comments on Kanis et al.: Algorithm for the management of patients at low, high, and very high risk of osteoporotic fractures. Osteoporosis International, 2020, 31, 1015-1015.	1.3	11
42	Factors associated with referral for osteoporosis care in men: a real-life study of a nationwide dataset. Archives of Osteoporosis, 2021, 16, 56.	1.0	11
43	The Use of Oral Amino-Bisphosphonates and Coronavirus Disease 2019 (COVID-19) Outcomes. Journal of Bone and Mineral Research, 2021, 36, 2177-2183.	3.1	11
44	Circulating Dickkopf-1 and sclerostin in patients with Paget's disease of bone. Clinical Rheumatology, 2017, 36, 925-928.	1.0	10
45	Effects of secukinumab on serum adipocytokines: preliminary data. Reumatismo, 2017, 69, 105.	0.4	9
46	Recent Advances in Imaging for Diagnosis, Monitoring, and Prognosis of Psoriatic Arthritis. Frontiers in Medicine, 2020, 7, 551684.	1.2	9
47	Ultrasonographic detection, definition and quantification of soft tissue oedema in psoriatic dactylitis. Medical Ultrasonography, 2019, 21, 414.	0.4	9
48	Bone health, an often forgotten comorbidity in systemic lupus erythematosus: a comment on the new recommendations. Annals of the Rheumatic Diseases, 2020, 79, e150-e150.	0.5	7
49	Different fracture risk profile in patients treated with anti-osteoporotic drugs in real-life. Reumatismo, 2020, 72, 71-74.	0.4	7
50	Amino-Bisphosphonates and Cardiovascular Risk: A New Hypothesis Involving the Effects on Gamma-Delta T Cells. Journal of Bone and Mineral Research, 2019, 34, 570-571.	3.1	7
51	Vitamin D: no efficacy without deficiency. What's new?. Reumatismo, 2019, 71, 57-61.	0.4	6
52	Wnt Inhibitors and Bone Turnover Markers in Patients With Polymyalgia Rheumatica and Acute Effects of Glucocorticoid Treatment. Frontiers in Medicine, 2020, 7, 551.	1.2	6
53	Vitamin D supplementation: much ado about nothing. Gynecological Endocrinology, 2020, 36, 185-189.	0.7	6
54	Rheumatoid arthritis, γδT cells and bisphosphonates. Annals of the Rheumatic Diseases, 2018, 77, e57-e57.	0.5	5

#	Article	IF	CITATIONS
55	Clinical profile and outcome of patients with chronic inflammatory arthritis and metabolic syndrome. Internal and Emergency Medicine, 2021, 16, 863-874.	1.0	5
56	Pharmacological treatment in adult patients with CRPS-I: a systematic review and meta-analysis of randomized controlled trials. Rheumatology, 2022, 61, 3534-3546.	0.9	5
57	Effectiveness of influenza vaccine in TNF inhibitors treated patients: comment on the article by Burmester et al. Annals of the Rheumatic Diseases, 2020, 79, e166-e166.	0.5	4
58	Correspondence on †Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco <i>et al</i> . Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases. Annals of the Rheumatic Diseases, 2022, 81, e222-e222.	0.5	4
59	Tumour necrosis factor inhibitors reduce aortic stiffness progression in patients with long-standing rheumatoid arthritis. Arthritis Research and Therapy, 2021, 23, 158.	1.6	4
60	A case of mandible Paget's disease of the bone treated with intravenous neridronate. Reumatismo, 2016, 68, 154-158.	0.4	3
61	Sex-Specific Association of Left Ventricular Hypertrophy With Rheumatoid Arthritis. Frontiers in Cardiovascular Medicine, 2021, 8, 676076.	1.1	3
62	Calcium and vitamin D supplementation: when and why. Minerva Obstetrics and Gynecology, 2021, 73, 704-713.	0.5	3
63	Is the exposure to bisphosphonates or osteoporosis the predictor of spinal radiographic progression in ankylosing spondylitis?. Arthritis Research and Therapy, 2018, 20, 233.	1.6	2
64	Usefulness of CHA2DS2â€VASc score to predict mortality and hospitalization in patients with inflammatory arthritis. International Journal of Rheumatic Diseases, 2020, 23, 106-115.	0.9	2
65	Could Previous Exposure to Nitrogenâ€Containing Bisphosphonates Mitigate Friendly Fire?. Journal of Bone and Mineral Research, 2020, 35, 2082-2082.	3.1	2
66	Pharmacodynamics of Oral Cholecalciferol in Healthy Individuals with Vitamin D Deficiency: A Randomized Open-Label Study. Nutrients, 2021, 13, 2293.	1.7	2
67	Acute Phase Reaction and Fracture Risk Reduction: Are Gamma-Delta T Cells and Hypovitaminosis D the Missing Link?. Journal of Bone and Mineral Research, 2020, 37, 1622-1622.	3.1	2
68	Real-life short-term effectiveness of anti-osteoporotic treatments: a longitudinal cohort study. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2211050.	1.2	2
69	AB0776â€18F-Fluoride PET/CT for Detection of Axial Involvement in Ankylosing Spondylitis:. Annals of the Rheumatic Diseases, 2015, 74, 1158.2-1158.	0.5	1
70	AB0313â€Short-Term Effects of Tnf Inhibitors on Bone Turnover Markers and Bone Mineral Density in Rheumatoid Arthritis:. Annals of the Rheumatic Diseases, 2016, 75, 1007.2-1008.	0.5	1
71	OP0107â€Teriparatide and Denosumab Combination Therapy and Skeletal Metabolism. Annals of the Rheumatic Diseases, 2016, 75, 95.2-95.	0.5	0
72	FRI0469â€CHANGES IN DKK-1, SCLEROSTIN, AND RANKL SERUM LEVELS FOLLOWING DISCONTINUATION OF LONG-TERM DENOSUMAB TREATMENT IN POSTMENOPAUSAL WOMEN. , 2019, , .		0

#	Article	IF	CITATIONS
73	OP0230â€EFFECTIVENESS OF INFLUENZA VACCINE IN TNF INHIBITORS TREATED PATIENTS. , 2019, , .		0
74	AB0831â€PERSPECTIVE ON THE CLINICAL PRACTICE MANAGEMENT OF HYPOVITAMINOSIS D FROM A MEETING OF ITALIAN EXPERTS. , 2019, , .)	0
75	Left ventricular hypertrophy predicts poorer cardiovascular outcome in normotensive normoglycemic patients with rheumatoid arthritis. International Journal of Rheumatic Diseases, 2021, 24, 510-518.	0.9	0
76	The troubling liaison between cancer and metabolic syndrome in chronic inflammatory rheumatic diseases. Arthritis Research and Therapy, 2021, 23, 89.	1.6	0
77	POS0218â€TUMOR-NECROSIS FACTOR INHIBITORS IMPROVE AORTIC STIFFNESS IN PATIENTS WITH LONGSTANDING RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases, 2021, 80, 326.2-327.	0.5	0
78	POS1173â€A SHORT DELAY IN ARTHRITIS CARE IS ASSOCIATED WITH HIGHER DISEASE ACTIVITY - LESSONS FR THE CORONAVIRUS DISEASE 19 (COVID-19) PANDEMIC. Annals of the Rheumatic Diseases, 2021, 80, 867.1-867.	OM 0.5	0
79	OP0178â€ASSOCIATION BETWEEN ENVIRONMENTAL AIR POLLUTION AND RHEUMATOID ARTHRITIS FLARES. Annals of the Rheumatic Diseases, 2021, 80, 106.1-107.	0.5	0
80	POS0644â€AIR POLLUTION IS A PREDICTOR OF POOR RESPONSE TO BIOLOGICAL THERAPIES IN CHRONIC INFLAMMATORY ARTHRITIDES. Annals of the Rheumatic Diseases, 2021, 80, 560.2-560.	0.5	0
81	POS1102â€TEMPORAL TRENDS AND FACTORS ASSOCIATED WITH VITAMIN D PRESCRIPTION AND INTAKE. Ann of the Rheumatic Diseases, 2021, 80, 831.1-832.	als 0.5	0
82	OP0112â€FACTORS ASSOCIATED WITH OSTEOPOROSIS CARE OF MEN: A REAL-LIFE STUDY ON A NATION-WID DATASET. Annals of the Rheumatic Diseases, 2021, 80, 62.1-62.	Е 0.5	0
83	SAT0652â€Study of nail unit with ultrasonography in several rheumatological conditions: a cross sectional study of distal interphalangeal joint and nail. , 2018, , .		0
84	AB0893â€THE EFFECTS OF THREE DIFFERENT VITAMIN D3 SUPPLEMENTATION REGIMENS IN DEFICIENT SUBJEC - A RANDOMIZED OPEN-LABEL PARALLEL GROUP STUDY Annals of the Rheumatic Diseases, 2020, 79, 1750.2-1751.	CTS 0.5	0
85	AB1094â€SCAR IMAGING ECHOCARDIOGRAPHY WITH ULTRASOUND MULTI-PULSE SCHEME [eSCAR] FOR THE DETECTION OF MYOCARDIAL FIBROSIS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: PRELIMINARY RESULTS Annals of the Rheumatic Diseases, 2020, 79, 1836.2-1836.	0.5	0
86	SAT0456â€REAL-LIFE RISK OF FRACTURE AND TREATMENT PREVALENCE IN DRUG-INDUCED OSTEOPOROSIS IN ITALY USING A NEW ALGORITHM. Annals of the Rheumatic Diseases, 2020, 79, 1185.1-1186.	0.5	0
87	Comment on: clinical efficacy of oral alendronate in ankylosing spondylitis: a randomised placebo-controlled trial. Clinical and Experimental Rheumatology, 2017, 35, 548.	0.4	0